Infigratinib
Medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Infigratinib?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Infigratinib, sold under the brand name Truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).[1][4]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Truseltiq |
Other names | BGJ-398 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621041 |
License data |
|
Pregnancy category | |
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H31Cl2N7O3 |
Molar mass | 560.48 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The most common side effects include increased phosphate level in the blood, increased creatinine levels in the blood, nail changes, mouth sores, dry eye, fatigue, alopecia, and palmar-plantar erythrodysesthesia (rash, redness, pain, swelling or blisters on the palms of the hands or soles of the feet).[5][6]
Infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2, and FGFR3.[4][7]
Infigratinib was approved for medical use in the United States in May 2021.[4][5][6][8][9]